Page last updated: 2024-10-16

adenine and Melanoma

adenine has been researched along with Melanoma in 20 studies

Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

Research Excerpts

ExcerptRelevanceReference
" In this study, we found that β-mangostin from seedcases of Garcinia mangostana inhibited α-melanocyte-stimulating hormone (α-MSH)-mediated melanogenesis in B16F10 melanoma cells and a three-dimensional human skin model."7.85Depigmentation of α-melanocyte-stimulating hormone-treated melanoma cells by β-mangostin is mediated by selective autophagy. ( Kim, KD; Lee, KW; Madhi, H; Oh, SS; Park, KH; Park, S; Ryu, HW; Yoo, J, 2017)
" In search of such a drug, we examined the efficacy of graveoline, a bioactive compound isolated from Ruta graveolens on skin melanoma A375 cells through the use of specific signaling cascades and their inhibitors."7.80Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway. ( Bishayee, K; Ghosh, S; Khuda-Bukhsh, AR, 2014)
"A group of 39 patients with malignant melanoma were treated with dacarbazine 1 g/m(2) i."7.70Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. ( Braybrooke, JP; Crawley, JE; Harris, AL; Houlbrook, S; O'Byrne, KJ; Propper, DJ; Shuker, DE; Stratford, IJ; Talbot, DC, 2000)
"2DG/rotenone failed to increase proautophagic beclin-1 and autophagic flux in melanoma cells despite the activation of AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin complex 1 (mTORC1)."5.623-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms. ( Bosnjak, M; Harhaji-Trajkovic, L; Kosic, M; Kravic-Stevovic, T; Mircic, A; Paunovic, V; Ristic, B; Stevanovic, D; Trajkovic, V, 2021)
" In this study, we found that β-mangostin from seedcases of Garcinia mangostana inhibited α-melanocyte-stimulating hormone (α-MSH)-mediated melanogenesis in B16F10 melanoma cells and a three-dimensional human skin model."3.85Depigmentation of α-melanocyte-stimulating hormone-treated melanoma cells by β-mangostin is mediated by selective autophagy. ( Kim, KD; Lee, KW; Madhi, H; Oh, SS; Park, KH; Park, S; Ryu, HW; Yoo, J, 2017)
" In search of such a drug, we examined the efficacy of graveoline, a bioactive compound isolated from Ruta graveolens on skin melanoma A375 cells through the use of specific signaling cascades and their inhibitors."3.80Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway. ( Bishayee, K; Ghosh, S; Khuda-Bukhsh, AR, 2014)
"We tested 17 malignant mucosal melanomas of the head and neck for the thymine (T)-->adenine (A) missense mutation at nucleotide 1796 in the BRAF gene using direct sequencing and a newly developed assay that uses a novel primer extension method (Mutector assay)."3.72Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. ( Begum, S; Cohen, Y; Esche, C; Goldenberg, D; Lavie, O; Rosenbaum, E; Sidransky, D; Westra, WH, 2004)
"A group of 39 patients with malignant melanoma were treated with dacarbazine 1 g/m(2) i."3.70Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. ( Braybrooke, JP; Crawley, JE; Harris, AL; Houlbrook, S; O'Byrne, KJ; Propper, DJ; Shuker, DE; Stratford, IJ; Talbot, DC, 2000)
"2DG/rotenone failed to increase proautophagic beclin-1 and autophagic flux in melanoma cells despite the activation of AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin complex 1 (mTORC1)."1.623-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms. ( Bosnjak, M; Harhaji-Trajkovic, L; Kosic, M; Kravic-Stevovic, T; Mircic, A; Paunovic, V; Ristic, B; Stevanovic, D; Trajkovic, V, 2021)
"The prognosis for malignant melanoma is poor; therefore, new diagnostic methods and treatment strategies are urgently needed."1.39Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells. ( Inui, M; Morita, H; Murata, T; Okumura, K; Shimizu, K; Tagawa, T, 2013)
"B16cOVA melanoma was implanted to TLR7 mice to evaluate the roles of stromal TLR7 on melanoma growth."1.37Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. ( Carson, DA; Chan, M; Corr, M; Cottam, HB; Daniels, GA; Hayashi, T; Norton, JT; Tawatao, RI; Wu, CC; Yao, S, 2011)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.00)18.2507
2000's3 (15.00)29.6817
2010's12 (60.00)24.3611
2020's4 (20.00)2.80

Authors

AuthorsStudies
Ren, S1
Wang, X2
Song, J1
Jin, G1
Misek, SA1
Newbury, PA1
Chekalin, E1
Paithankar, S1
Doseff, AI1
Chen, B1
Gallo, KA1
Neubig, RR1
Zhang, L1
Ji, Z1
Zhang, J1
Yang, S1
Moschos, SJ1
Eroglu, Z1
Khushalani, NI1
Kendra, KL1
Ansstas, G1
In, GK1
Wang, P1
Liu, G1
Collichio, FA1
Googe, PB1
Carson, CC1
McKinnon, K1
Wang, HH1
Nikolaishvilli-Feinberg, N1
Ivanova, A1
Arrowood, CC1
Garrett-Mead, N1
Conway, KC1
Edmiston, SN1
Ollila, DW1
Serody, JS1
Thomas, NE1
Ivy, SP1
Agrawal, L1
Dees, EC1
Abbruzzese, JL1
Kosic, M1
Paunovic, V1
Ristic, B1
Mircic, A1
Bosnjak, M1
Stevanovic, D1
Kravic-Stevovic, T1
Trajkovic, V1
Harhaji-Trajkovic, L1
Misra, SK1
Kampert, TL1
Pan, D1
Sinik, L1
Minson, KA1
Tentler, JJ1
Carrico, J1
Bagby, SM1
Robinson, WA1
Kami, R1
Burstyn-Cohen, T1
Eckhardt, SG1
Frye, SV1
Earp, HS1
DeRyckere, D1
Graham, DK1
Del Bello, B1
Toscano, M1
Moretti, D1
Maellaro, E1
Ghosh, S1
Bishayee, K1
Khuda-Bukhsh, AR1
Hiramoto, K1
Murata, T2
Shimizu, K2
Morita, H2
Inui, M2
Manganiello, VC1
Tagawa, T2
Arai, N1
Lee, KW1
Ryu, HW1
Oh, SS1
Park, S1
Madhi, H1
Yoo, J1
Park, KH1
Kim, KD1
Hayashi, T1
Chan, M1
Norton, JT1
Wu, CC1
Yao, S1
Cottam, HB1
Tawatao, RI1
Corr, M1
Carson, DA1
Daniels, GA1
Martin, L1
Jiang, YY1
Yang, R1
Wang, HJ1
Huang, H1
Wu, D1
Tashiro, S1
Onodera, S1
Ikejima, T1
Hammerová, J1
Uldrijan, S1
Táborská, E1
Vaculová, AH1
Slaninová, I1
Okumura, K1
Cohen, Y1
Rosenbaum, E1
Begum, S1
Goldenberg, D1
Esche, C1
Lavie, O1
Sidransky, D1
Westra, WH1
Berrahmoune, H1
Herbeth, B1
Lamont, JV1
Masson, C1
FitzGerald, SP1
Visvikis-Siest, S1
Imperatori, L1
Damia, G1
Taverna, P1
Garattini, E1
Citti, L1
Boldrini, L1
D'Incalci, M1
Braybrooke, JP1
Houlbrook, S1
Crawley, JE1
Propper, DJ1
O'Byrne, KJ1
Stratford, IJ1
Harris, AL1
Shuker, DE1
Talbot, DC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance[NCT02581930]Phase 218 participants (Actual)Interventional2016-08-17Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Subjects With Antitumor Response as Evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria 1.1

Antitumor response defined as the sum of complete response (CR) and partial response (PR). CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm (<1 cm). PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT02581930)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Treatment (Ibrutinib)0

Overall Survival

Estimated using the Kaplan Meier method. (NCT02581930)
Timeframe: Duration of time from day 1 of treatment to death as a result of any cause, assessed up to 1 year

Interventionmonths (Median)
Treatment (Ibrutinib)6

Progression Free Survival

Progression free survival (PFS) is defined as the duration of time from Day 1 of treatment to time of progression (based on clinical or radiographic grounds) or death as a result of any cause, whichever occurs first. (NCT02581930)
Timeframe: 1 year

Interventionmonths (Median)
Treatment (Ibrutinib)1.3

Reviews

1 review available for adenine and Melanoma

ArticleYear
[What's new in dermatological treatments?].
    Annales de dermatologie et de venereologie, 2010, Volume: 137 Suppl 4

    Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic

2010

Trials

1 trial available for adenine and Melanoma

ArticleYear
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
    Melanoma research, 2021, 04-01, Volume: 31, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Interleukin-2; Male; Melanoma; Melanoma, Cu

2021

Other Studies

18 other studies available for adenine and Melanoma

ArticleYear
Discovery of novel ibrutinib analogues to treat malignant melanoma.
    Bioorganic chemistry, 2021, Volume: 117

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell P

2021
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
    Molecular pharmacology, 2022, Volume: 101, Issue:1

    Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; D

2022
Photodynamic therapy enhances skin cancer chemotherapy effects through autophagy regulation.
    Photodiagnosis and photodynamic therapy, 2019, Volume: 28

    Topics: Adenine; Aminolevulinic Acid; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferat

2019
3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms.
    Journal of pharmacological sciences, 2021, Volume: 147, Issue:1

    Topics: Adenine; AMP-Activated Protein Kinases; Animals; Autophagy; Cell Death; Deoxyglucose; JNK Mitogen-Ac

2021
Nano-Assembly of Pamitoyl-Bioconjugated Coenzyme-A for Combinatorial Chemo-Biologics in Transcriptional Therapy.
    Bioconjugate chemistry, 2018, 04-18, Volume: 29, Issue:4

    Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Coenzyme A; Drug Carriers; Humans; Melanoma; Nanop

2018
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
    Molecular cancer therapeutics, 2019, Volume: 18, Issue:2

    Topics: Adenine; Animals; Azetidines; c-Mer Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Cell Surv

2019
Cisplatin-induced apoptosis inhibits autophagy, which acts as a pro-survival mechanism in human melanoma cells.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Adaptor Proteins, Vesicular Transport; Adenine; Antimetabolites, Antineoplastic; Antineoplastic Agen

2013
Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway.
    Phytotherapy research : PTR, 2014, Volume: 28, Issue:8

    Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Humans; Me

2014
Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells.
    Cellular signalling, 2014, Volume: 26, Issue:9

    Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenine; Cell Line, Tumor; Cell Movement; Cell Proliferation

2014
Depigmentation of α-melanocyte-stimulating hormone-treated melanoma cells by β-mangostin is mediated by selective autophagy.
    Experimental dermatology, 2017, Volume: 26, Issue:7

    Topics: Adenine; alpha-MSH; Animals; Autophagy; Cell Survival; Garcinia mangostana; Humans; Inflammation; Me

2017
Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
    Melanoma research, 2011, Volume: 21, Issue:1

    Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Synergism; Female; Flow C

2011
Mechanism of autophagy induction and role of autophagy in antagonizing mitomycin C-induced cell apoptosis in silibinin treated human melanoma A375-S2 cells.
    European journal of pharmacology, 2011, May-20, Volume: 659, Issue:1

    Topics: Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Down-Regulation; Humans; Melanoma; Mitomycin; NF-ka

2011
Necroptosis modulated by autophagy is a predominant form of melanoma cell death induced by sanguilutine.
    Biological chemistry, 2012, Volume: 393, Issue:7

    Topics: Adenine; Antineoplastic Agents; Autophagy; Benzophenanthridines; Caspases; Cell Line, Tumor; Cell Su

2012
Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells.
    Oncology reports, 2013, Volume: 29, Issue:4

    Topics: Adenine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Typ

2013
Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-15, Volume: 10, Issue:10

    Topics: Adenine; DNA; Exons; Head and Neck Neoplasms; Humans; Melanocytes; Melanoma; Models, Genetic; Mutage

2004
Lack of association between EGF 61A>G polymorphism and plasma EGF concentration in the STANISLAS family study.
    The Journal of investigative dermatology, 2007, Volume: 127, Issue:4

    Topics: Adenine; Epidermal Growth Factor; Guanine; Humans; Melanoma; Osmolar Concentration; Polymorphism, Ge

2007
3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents.
    Carcinogenesis, 1994, Volume: 15, Issue:3

    Topics: 3T3 Cells; Adenine; Alkylating Agents; Animals; Drug Resistance; Escherichia coli; Gene Expression R

1994
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:2

    Topics: Adenine; Adult; Aged; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Damage; Femal

2000